Workflow
海正药业(600267) - 2024 Q4 - 年度业绩预告(更正)
600267HISUN(600267)2025-01-22 09:55

Financial Performance Expectations - The company expects a net profit attributable to shareholders of between 570 million and 630 million yuan for the year 2024, marking a turnaround from a loss in the previous year[2] - The net profit after deducting non-recurring gains and losses is projected to be between 400 million and 460 million yuan for 2024[2] - In the same period last year, the company reported a net loss of 931.71 million yuan, indicating a significant improvement in performance[4] Factors Contributing to Profit - The company attributes the expected profit to marketing transformation, overcoming product price declines, and significant improvements in operational efficiency[5] - The company anticipates an increase in investment income of approximately 155 million yuan due to the redemption of convertible bonds, contributing to non-recurring gains[5] Earnings Forecast and Audit - The earnings forecast has been preliminarily discussed with the accounting firm, with no significant discrepancies noted[3] - The company has not identified any major uncertainties that could impact the earnings forecast[6] - The financial data provided is preliminary and subject to final audit in the official annual report[7]